Trinity Biotech plc

NasdaqGS:TRIB Stock Report

Market Cap: US$8.9m

Trinity Biotech Future Growth

Future criteria checks 1/6

Trinity Biotech is forecast to grow earnings and revenue by 33.2% and 11.8% per annum respectively while EPS is expected to grow by 55.6% per annum.

Key information

33.2%

Earnings growth rate

55.6%

EPS growth rate

Medical Equipment earnings growth16.5%
Revenue growth rate11.8%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

Recent updates

Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

Sep 25
Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

Aug 07
A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Jun 11
The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Mar 02
Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Dec 18
Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Sep 12
A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Aug 08
Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Jun 09
Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

Apr 23
Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Apr 23
This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Mar 01
Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Trinity Biotech appoints former GE executive Aris Kekedjian as CEO

Oct 03

At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Sep 01
At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M

Jun 30

Earnings and Revenue Growth Forecasts

NasdaqGS:TRIB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202678-8361
12/31/202569-15-11-81
12/31/202462-20-10-91
9/30/202459-20-16-7N/A
6/30/202459-22-14-8N/A
3/31/202457-34-15-12N/A
12/31/202357-37-14-12N/A
9/30/202371-39-13-10N/A
6/30/202354-46-8-5N/A
3/31/202374-34-7-2N/A
12/31/202263-44-7-1N/A
9/30/202276-32-62N/A
6/30/202279-22-53N/A
3/31/202286-13-26N/A
12/31/202181-2513N/A
9/30/2021106-81120N/A
6/30/2021116-21827N/A
3/31/2021106-21929N/A
12/31/2020102-61424N/A
9/30/202091-20-17N/A
6/30/202083-27-65N/A
3/31/202090-31-210N/A
12/31/201990-29-65N/A
9/30/201994-30-411N/A
6/30/201993-29-79N/A
3/31/201995-23-79N/A
12/31/201897-23-107N/A
9/30/201897-39-107N/A
6/30/201899-40N/A8N/A
3/31/201899-40N/A10N/A
12/31/201799-39N/A9N/A
9/30/201798-36N/A8N/A
6/30/201799-37N/A10N/A
3/31/2017100-36N/A8N/A
12/31/2016100-39N/A10N/A
9/30/20161013N/A17N/A
6/30/201610116N/A14N/A
3/31/20169816N/A13N/A
12/31/201510022N/A13N/A
9/30/201510123N/A15N/A
6/30/201510315N/A17N/A
3/31/201510517N/A16N/A
12/31/201410515N/A16N/A
9/30/201410318N/A8N/A
6/30/201410010N/A6N/A
3/31/20149510N/A8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRIB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TRIB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TRIB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TRIB's revenue (11.8% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: TRIB's revenue (11.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TRIB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 10:09
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Trinity Biotech plc is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura McGuiganB. Riley Securities, Inc.
Lawrence SolowCJS Securities, Inc.
William BonelloCraig-Hallum Capital Group LLC